This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L10.2 (Pemphigus foliaceus) | Special Copayment Reduction: V210 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood: very high — pemphigus foliaceus occurs at any age in adulthood and is especially common in people in their 40s–60s. Because there is no oral mucosal involvement, it is often initially mistaken for seborrheic dermatitis or other skin diseases, and months to years may pass from symptom onset to confirmation. |
| 1. History | 1926: first description by Cazenave → identification of DSG1 as the target antigen → studies of the regional endemic Brazilian pemphigus foliaceus (Fogo selvagem). |
| 2. Causes | IgG autoantibodies against desmoglein 1 (DSG1). Acantholysis in the upper epidermis (granular layer). The Brazilian endemic form is suspected to be associated with the Simulium purpurascens blood-sucking fly. |
| 3. Genetics | Associated with HLA-DRB1*04:01 and DRB1*14. A distinctive HLA profile in the Brazilian form. No pathogenic variants in the DSG1 gene itself. |
| 4. General epidemiology | Rarer than or about as frequent as pemphigus vulgaris. Regional endemic form in some rural areas of Brazil. Most common in people in their 40s–60s; can occur in children. |
| 5. Pathophysiology | Anti-DSG1 IgG → acantholysis in the upper epidermis (where DSG1 is predominantly expressed) → shallow subcorneal blisters. No oral mucosal involvement (DSG3 compensation). |
| 6. Symptoms | Erythematous, scaly, crusted lesions in a seborrheic distribution, no oral mucosal lesions, positive Nikolsky sign, may progress to generalized erythroderma. |
| 7. Signs | Shallow erosions and scaly crusts, positive Nikolsky sign, epidermal denudation, pigmentary changes. Milder than pemphigus vulgaris, but severe with erythroderma. |
| 8. Screening | Anti-DSG1 ELISA, IIF. Actively performed in patients with recurrent skin lesions in a seborrheic distribution. |
| 9. Diagnosis | Histopathology (acantholysis in the upper epidermis), DIF (intercellular IgG net-like deposition between keratinocytes), positive anti-DSG1 on ELISA. |
| 10. Treatment | Systemic steroids, rituximab, combined with azathioprine or mycophenolate. Topical steroids alone may suffice in mild cases. |
| 11. Prognosis | Better prognosis than pemphigus vulgaris. High remission rate. Becomes severe if it progresses to erythroderma. |
| 12. Prevention | Maintenance treatment, UV protection, avoidance of triggering drugs, infection prevention. |
| 13. References | Schmidt E et al. Lancet 2019 and 9 others. |
Pemphigus Foliaceus was first described in 1926 by the French dermatologist Pierre Louis Alphée Cazenave as a 'superficial form of pemphigus', characterized by shallow blisters close to the skin surface and scales and crusts that peel off like fallen leaves. Its name derives from the visual feature that the skin surface is easily shed, like falling leaves. After Cazenave's description in the early 20th century, pemphigus foliaceus was clinically distinguished from pemphigus vulgaris; the key differences were the absence of oral mucosal lesions and shallower blisters.
Historically, the most noted form of pemphigus foliaceus is the Brazilian regional endemic pemphigus foliaceus, 'Fogo Selvagem (wild fire)'. This disease was observed as if endemic for decades in rural areas of central-western Brazil and occurred in clusters among residents of certain areas and Indigenous people. In the 1940s–60s, Brazilian dermatologists defined the disease and described its epidemiology, and an association with an environmental factor (blood-sucking flies of the genus Simulium) was subsequently proposed. Since the 1970s, a tendency for the endemic to decline in certain areas within Brazil has been observed, but cluster outbreaks have also been reported in new areas.
Understanding at the molecular level advanced greatly when, in 1981, John Stanley et al. first partially purified the target antigen of autoantibodies in the sera of patients with pemphigus foliaceus and later, in 1994, confirmed it to be desmoglein 1 (DSG1). It was established that whereas in pemphigus vulgaris suprabasal acantholysis occurs due to DSG3 autoantibodies, in pemphigus foliaceus shallow acantholysis in the upper epidermis (at the level of the granular layer) occurs due to DSG1 autoantibodies. This discovery led to the development of the 'desmoglein compensation theory'. Treatment, as for pemphigus vulgaris, centers on corticosteroids and immunosuppressants, and the efficacy of rituximab in treating pemphigus foliaceus has also been confirmed in several studies.
Recently, awareness has grown of the subtype classification of pemphigus foliaceus and of drug-induced pemphigus foliaceus caused by certain drugs (penicillamine, ACE inhibitors, as well as tyrosine kinase inhibitors, etc.). Studies have also been published suggesting that an IgE-mediated mechanism may be involved in some patients, which is drawing attention in connection with reports of pemphigus foliaceus developing after dupilumab administration.
Pemphigus foliaceus is caused by IgG autoantibodies against desmoglein 1 (DSG1), a desmosomal protein of the epidermis. DSG1 is expressed mainly in the upper layers of the epidermis (spinous and granular layers), and in the oral mucosa DSG3 complements (compensates for) the function of DSG1, so oral mucosal lesions do not occur in pemphigus foliaceus. This is the 'desmoglein compensation theory', which explains the key clinical difference between pemphigus vulgaris (targeting DSG3) and pemphigus foliaceus.
The target epitope of the autoantibodies is mainly the extracellular domain EC1 of DSG1, and the IgG4 subclass predominates. The pathogenic mechanism is explained by the combined action of steric hindrance of trans-binding between DSG1 molecules and activation of intracellular signaling (p38 MAPK, Src kinase). In the basal layer of the epidermis and in mucosa, where DSG1 expression is relatively low, autoantibody-induced acantholysis does not occur, so blisters are confined to the upper epidermis (just below the granular layer or just above the stratum corneum).
HLA class II genes are important as genetic predisposing factors for pemphigus foliaceus. Alleles such as HLA-DRB1*04:01 and HLA-DRB1*14 have been reported as risk factors. A distinctive HLA profile (HLA-DRB1*04:04, DRB1*14:01, etc.) is observed in Brazilian Fogo Selvagem patients. Pathogenic variants in the DSG1 gene (18q12.1) itself are not the cause of pemphigus foliaceus, and Peeling Skin Syndrome type B caused by variants in this gene is a separate disease.
Environmental factors are strongly suggested in the pathogenesis of Brazilian regional endemic pemphigus foliaceus (Fogo Selvagem). In particular, there is a hypothesis that an immune response to antigens contained in the saliva of Simulium nigrimanum (a black blood-sucking fly) induces autoantibodies cross-reactive with DSG1. In fact, there is epidemiological evidence that the risk increases when urban migrants who have not been exposed to the flies begin living in rural areas, and that autoantibody titers decrease when they stop living in rural areas. Common causes of drug-induced pemphigus foliaceus include penicillamine, captopril, bucillamine, and pyritinol, and the thiol group (-SH) in the drug structure is presumed to induce autoimmunity by modifying DSG1 or the antigen-presentation process.
Like pemphigus vulgaris, pemphigus foliaceus is a complex genetic disease and is not caused by a single-gene variant. HLA class II genes are mainly cited as genetic risk factors, and in particular specific alleles of the HLA-DRB1 and HLA-DQB1 genes located on chromosome 6 (6p21.3) are associated with risk.
In sporadic pemphigus foliaceus, associations with HLA-DRB1*01:01, HLA-DRB1*04:01, HLA-DRB1*14, etc. have been reported in European and North American populations. In the Brazilian Fogo Selvagem patient population, HLA-DRB1*04:04, HLA-DRB1*14:01, HLA-DQB1*03:02, etc. are observed at high frequency, and strong associations were confirmed in HLA comparison studies with unaffected Brazilian Indigenous people. It has been hypothesized that these specific HLA genotypes have a structure that readily presents specific epitopes of blood-sucking fly salivary antigens in a DSG1 cross-reactive manner.
Variants in the coding region of the DSG1 gene itself are not a direct cause of pemphigus foliaceus. Heterozygous loss-of-function (LOF) mutations in the DSG1 gene cause a peeling skin disorder (SAM syndrome, OMIM 615927), which is a disease of skin barrier defects due to absence of the DSG1 protein, not an autoimmune mechanism. The implications of genetic counseling for pemphigus foliaceus are limited, and the risk of recurrence within a family is low.
Pemphigus foliaceus is a rare autoimmune blistering disease worldwide. The annual incidence in Western countries is approximately 1–2 per million population, similar to or slightly lower than that of pemphigus vulgaris. However, in certain rural areas of Brazil (such as the state of Mato Grosso do Sul), regional endemic cluster outbreaks in the form of Fogo Selvagem have been reported, and the incidence may be dozens of times higher.
Like pemphigus vulgaris, onset is most common in people in their 40s–60s, but onset in children and adolescents is relatively more common than in pemphigus vulgaris. Fogo Selvagem also occurs in children and adolescents, and in some studies onset at age 20 or younger accounts for a considerable proportion. Regarding sex distribution, the adult form shows a slight female predominance or a similar distribution.
In Korea, pemphigus foliaceus is reported less often than pemphigus vulgaris, and the number of patients registered under the L10.2 code in Health Insurance Review & Assessment Service (HIRA) data is estimated at several dozen to several hundred per year. Because the frequency of specific HLA types associated with pemphigus foliaceus in East Asian populations may differ from that in Western populations, there may be differences in clinical presentation and epidemiology. Drug-induced pemphigus foliaceus has a high incidence in populations using certain drugs, and its proportion is higher in populations with greater exposure to the causative drugs.
The core pathophysiology of pemphigus foliaceus is acantholysis in the upper epidermis caused by anti-DSG1 IgG autoantibodies. DSG1 is highly expressed in the spinous and granular layers of the epidermis, while its expression is low in the basal layer. Therefore, acantholysis caused by anti-DSG1 antibodies occurs only in the upper epidermis, histologically forming very shallow subcorneal or granular-layer-level blisters.
The reason pemphigus foliaceus blisters do not form in the oral mucosa is explained by the 'desmoglein compensation theory'. In the epithelial cells of the oral mucosa, DSG3 is co-expressed even in the superficial layers, compensating for the loss of DSG1 function. In contrast, there is almost no DSG3 expression in the upper epidermis of the skin, so loss of DSG1 function leads directly to acantholysis. This theory elegantly explains the clinical patterns of each type of pemphigus — pemphigus vulgaris (DSG3 ± DSG1): oral + skin; pemphigus foliaceus (DSG1 alone): skin only; oral-type pemphigus vulgaris (DSG3 alone): oral only.
As in pemphigus vulgaris, the mechanism of autoantibody induction involves activation of DSG1-specific CD4+ T helper cells, Tfh differentiation, and production of high-affinity IgG4 antibodies by B cells. In Brazilian Fogo Selvagem, there is a hypothesis that protein epitopes among blood-sucking fly salivary antigens that are structurally similar to the extracellular domain of DSG1 activate autoreactive B cells by molecular mimicry, and there is experimental evidence that some fly salivary proteins show cross-reactivity with DSG1 autoantibodies. The fact that lesions mainly begin in a seborrheic distribution (scalp, face, chest, back) is presumed to be because DSG1 expression is relatively high in areas of UV exposure and sebum secretion, or because the immune microenvironment favors the pathogenic expression of autoantibodies.
The most important clinical feature of pemphigus foliaceus is the absence of oral mucosal lesions. This is the element that most easily distinguishes pemphigus vulgaris from pemphigus foliaceus clinically. Patients mainly present with shallow blisters, scales, crusts, and erythema in areas of seborrheic distribution, such as the scalp, face (nose, cheeks, forehead), upper chest, and interscapular region (upper back). Initially, it is frequently mistaken for seborrheic dermatitis, impetigo, or pityriasis rosea.
Because the blisters are very shallow and fragile and rupture easily, it is rare for patients to present with intact blisters. Most patients present with erosions covered by scales or crusts, desquamation, and erythema. The crusts are yellowish-brown, thick, and lamellar, and after removal, moist and painful erosions are revealed. The Nikolsky sign is positive, and when lateral pressure is applied to the skin around the border, the epidermis separates easily. Initially it is localized to seborrheic areas, but as it progresses it can spread to the limbs and the entire trunk.
With generalized involvement, it can progress to generalized erythroderma, in which case the risks of loss of skin barrier function, fluid and electrolyte imbalance, impaired thermoregulation, and secondary bacterial infection increase greatly, requiring inpatient treatment. Because pemphigus foliaceus, unlike pemphigus vulgaris, lacks oral mucosal involvement, there is no difficulty eating or swallowing, and overall systemic symptoms are also mild. However, with extensive skin involvement, pain, pruritus, sleep disturbance, and a sense of social isolation greatly affect quality of life. Photosensitivity is reported in some patients, and lesions tend to worsen after UV exposure.
The physical signs of pemphigus foliaceus are generally shallower and milder than those of pemphigus vulgaris. Because blisters form in the upper epidermis, they rupture easily without a thick wall, so on examination erosions covered with scaly crusts are mainly observed rather than intact blisters. The crusts are yellowish-brown or brown and tend to build up thickly in a lamellar structure, and on removal hemorrhagic erosions are revealed.
Nikolsky sign: positive when lateral pressure applied to apparently normal skin easily separates the upper epidermis. Unlike pemphigus vulgaris, the full thickness of the epidermis does not separate; only the superficial stratum corneum moves like a slide. The Asboe-Hansen sign is also observed as positive. Scalp lesions appear as erosive scalp dermatitis, lamellar scales, and crusts, and may be accompanied by hair loss. Facial lesions, with a butterfly-shaped erythematous crusted distribution, may be confused with systemic lupus erythematosus (SLE).
On physical examination, the oral mucosa, conjunctiva, and anogenital mucosa are normal, which is an important distinguishing point in clinical diagnosis. The distribution of skin lesions is systematically evaluated and the extent of body surface area involvement is recorded. The PDAI (Pemphigus Disease Area Index) or ABSIS (Autoimmune Bullous Skin Disorder Intensity Score) is used to assess severity. When there are signs of generalized erythroderma (diffuse erythema, fine scaling, feeling of heat, lymphadenopathy, generalized edema), immediate inpatient evaluation is needed.
Laboratory findings include a positive anti-DSG1 ELISA (negative anti-DSG3 is typical) and intercellular net-like IgG deposition between keratinocytes on direct immunofluorescence (DIF). With extensive skin involvement, hypoalbuminemia, elevated CRP, and eosinophilia may be observed.
Pemphigus foliaceus has no oral mucosal lesions and begins with relatively mild skin lesions, so initial diagnosis is often delayed. When scaly, crusted, or erosive lesions in a seborrheic distribution persist for 2 weeks or more or do not respond to general treatment, or when the Nikolsky sign is positive, pemphigus foliaceus is suspected and screening tests are performed.
Serum anti-DSG1 ELISA is the primary screening test for pemphigus foliaceus, with a sensitivity of about 80–95% and a specificity of about 95% or more. A negative anti-DSG3 ELISA is typical of pemphigus foliaceus, and using both tests together also helps differentiate it from pemphigus vulgaris. Anti-DSG1 ELISA values are generally proportional to disease activity and can be used to monitor treatment response. When test results are borderline, confirmation is by IIF and biopsy DIF.
Indirect immunofluorescence (IIF): on frozen sections of monkey esophagus, both pemphigus foliaceus and pemphigus vulgaris show positive intercellular net-like IgG fluorescence between keratinocytes, so ELISA is more useful for distinguishing the two diseases. When human skin is used as the substrate, the location of antibody binding (upper epidermis vs full thickness) may differ, but distinction is generally difficult. Measuring the IIF titer allows indirect assessment of treatment response.
Biopsy and DIF are the standard for confirming pemphigus foliaceus. A 4 mm punch biopsy is taken from the border of a fresh blister or erosion and preserved in Michel's solution for DIF, and formalin-fixed tissue is taken from an adjacent site for H&E histopathology. When drug-induced pemphigus foliaceus is suspected, review of the list of medications taken is essential.
The diagnosis of pemphigus foliaceus is made by integrating clinical features, histopathology, DIF, and serum autoantibody tests. Histopathology and DIF must be performed for confirmation, and the type of autoantibody is identified by serum ELISA to differentiate it from pemphigus vulgaris.
Histopathology: the typical finding of pemphigus foliaceus on H&E staining is acantholysis and blister formation in the upper epidermis (just below the granular layer or stratum corneum). Unlike pemphigus vulgaris, with its suprabasal cleft, the blister is located at a very shallow level. Acantholytic keratinocytes (acantholytic cells, Tzanck cells) are observed within the blister, and neutrophil and eosinophil infiltration may be present. To differentiate from IgA pemphigus, DIF is checked for IgA deposition.
Direct immunofluorescence (DIF): intercellular net-like deposition of IgG (and C3) between keratinocytes is observed in normal skin near the lesion, the same pattern as in pemphigus vulgaris. The sensitivity of DIF in pemphigus foliaceus is about 80–90%, which may be slightly lower than in pemphigus vulgaris, and false negatives are possible especially when lesions are mild or during treatment.
Serum ELISA: anti-DSG1 positive and anti-DSG3 negative is the typical pattern of pemphigus foliaceus. In pemphigus vulgaris (mucocutaneous type), both anti-DSG1 and anti-DSG3 are positive, so ELISA results need to be interpreted in conjunction with the clinical picture. Anti-DSG1 ELISA titers are generally proportional to disease activity and are used to track treatment response. Because anti-DSG1 may also be positive in drug-induced pemphigus foliaceus, the drug history must always be checked as well.
Treatment of pemphigus foliaceus follows principles similar to those for pemphigus vulgaris, but because its course is generally more favorable than pemphigus vulgaris, remission can often be induced with lower steroid doses. For mild localized lesions, topical corticosteroids alone are also effective.
Systemic corticosteroids: in moderate to severe pemphigus foliaceus, treatment is started with prednisolone 0.5–1 mg/kg/day and tapered gradually according to clinical response. Compared with pemphigus vulgaris, a lower initial dose is often sufficient. In drug-induced pemphigus foliaceus, remission is commonly achieved with short-term steroid use after discontinuing the causative drug.
Rituximab: used in combination with corticosteroids in moderate to severe cases or in patients who fail steroid tapering. The effect of rituximab in inducing complete remission has also been confirmed in several cohort studies of pemphigus foliaceus, and the 2020 EDF guidelines also recommend rituximab for moderate to severe pemphigus foliaceus.
Steroid-sparing immunosuppressants: azathioprine (1–3 mg/kg/day) and mycophenolate mofetil (2–3 g/day) are used for steroid tapering and maintenance of remission. Chloroquine or hydroxychloroquine has been reported to have some adjunctive effect in mild pemphigus foliaceus and may be helpful in combination with UV protection in patients with photosensitivity.
Topical treatment: in mild localized pemphigus foliaceus, good results can be obtained with high-potency topical corticosteroids (class I–II) alone or in combination with systemic treatment. Wet dressings, antibacterial ointments, and in some cases calcineurin inhibitors (tacrolimus, pimecrolimus) are used as adjuncts.
The prognosis of pemphigus foliaceus is generally better than that of pemphigus vulgaris. This is because there is no oral mucosal involvement and the blisters are shallow, so the risk of secondary infection is relatively low, and remission can often be induced with lower doses of immunosuppressants. The treatment remission rate of pemphigus foliaceus is reported to be similar to or higher than that of pemphigus vulgaris.
Complete remission is achieved in about 30–60% within 1–2 years of starting treatment. Some patients maintain long-term remission even after discontinuing immunosuppressants, and in the event of relapse, remission can mostly be induced again with retreatment. Drug-induced pemphigus foliaceus often reaches remission within weeks to months after discontinuing the causative drug, so its prognosis is particularly good. Fogo Selvagem patients tend to have decreased autoantibody titers and improvement of disease when they leave the area (fly habitat).
Poor prognostic factors include progression to generalized erythroderma, secondary infection (especially sepsis), advanced age, extensive body surface area involvement, and adverse effects of immunosuppressants. Generalized erythroderma increases the risk of death from fluid loss, sepsis, and impaired thermoregulation, so immediate hospitalization and intensive management are needed. In the long-term course, corticosteroid-related complications (osteoporosis, diabetes, infection) affect quality of life and morbidity.
As with pemphigus vulgaris, primary prevention of pemphigus foliaceus is not possible. The focus of prevention is on preventing relapse, preventing complications, and avoiding triggers. In drug-induced pemphigus foliaceus, identifying and avoiding the causative drug is the most important preventive strategy. When skin symptoms develop in patients taking thiol-containing drugs (penicillamine, bucillamine, captopril, pyritinol, etc.), the possibility of pemphigus foliaceus should be considered immediately.
Maintenance treatment to prevent relapse: even after complete remission, immunosuppressive treatment is not stopped abruptly but tapered gradually. Conversion of anti-DSG1 ELISA to negative and of DIF to negative is used as an indicator for discontinuing treatment, together with clinical judgment. Regular maintenance administration of rituximab also helps reduce the relapse rate of pemphigus foliaceus.
UV protection: because there is evidence that UV exposure is associated with lesion worsening in pemphigus foliaceus, the use of sunscreen, wearing protective clothing, and avoiding direct sunlight are recommended for patients with photosensitivity. For residents of Brazilian Fogo Selvagem risk areas, long-sleeved clothing, installation of insect screens, and use of repellents help reduce exposure to blood-sucking flies. Infection prevention and prevention of steroid adverse effects are managed on the same principles as for pemphigus vulgaris.